This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Karmanos Cancer Center's Blood And Marrow Stem Cell Transplant Program Receives Full Accreditation From Foundation

DETROIT, June 24, 2013 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Center's Blood and Marrow Stem Cell Transplant Program (BMT) has received full accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) – the highest level and the most extensive spectrum of accreditation offered by FACT for Bone Marrow Transplant Programs. 

(Photo: http://photos.prnewswire.com/prnh/20130624/DC36562 )

(Logo: http://photos.prnewswire.com/prnh/20071106/KARMANOSLOGO )

This includes accreditation for both adult and pediatric clinical programs, apheresis collection, marrow harvest collection and stem cell processing. The accreditation is effective for three years beginning Sept. 30, 2012.

Additionally, Karmanos' BMT program, the largest of its kind in Michigan, was honored with an award for being a site that has maintained continuous FACT accreditation for ten years or more. Karmanos' first FACT accreditation was received in 2000. 

"We are extremely pleased about receiving full accreditation from FACT," said Toni Henderson-Clark, MSN, MSBA, RN, CCRN, quality and regulatory specialist for the Blood and Marrow Stem Cell Transplant Program at Karmanos. "We make it an absolute priority to provide the best and most effective therapies for those patients who come to us for bone marrow transplants. The fact that we have maintained FACT accreditation for so long speaks to that commitment."

Karmanos doctors performed 273 bone marrow transplants in 2012 and expect to perform around 300 this year. The program also has been honored in the past by the National Marrow Donor Program (NMDP) for facilitating 25,000 transplants via its registry, as well as performing 250 marrow collections on behalf of the national program.

FACT-accredited organizations are required to fulfill the ongoing, rigorous standards set forth and to complete annual reports prior to the 12 th and 24 th month of their current accreditation cycle.

FACT, founded in 1996 and based at the University of Nebraska, establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a non-profit corporation co-founded by the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT) for the purposes of voluntary inspection and accreditation in the field of cellular therapy.

About the Barbara Ann Karmanos Cancer Institute Located in mid-town Detroit, Michigan, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for nearly 6,000 new patients annually on a budget of $265 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D. is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to www.karmanos.org .

SOURCE Karmanos Cancer Institute

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,084.19 -29.35 -0.17%
S&P 500 1,985.36 +1.83 0.09%
NASDAQ 4,468.3450 +12.3290 0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs